


How Do We Facilitate the Implementation of Needed Novel HTA Methodologies in National and EU HTA Practice?



18 November 2024, Barcelona, ISPOR Europe 2024



Oresta Piniazhko, PhD

Director of HTA Department State Expert Centre,
Ministry of Health, Ukraine

ISPOR Central and Eastern Europe Consortium Chair,
ISPOR Ukraine Chapter President

Agenda

- Current HTA landscape in Ukraine
- GAP analysis of methods
- Perspectives for improvement of HTA methods in the nearest future






Overview of HTA tool in Ukraine: legislation, processes and methods



National legal framework for HTA in Ukraine: current state and perspectives

Strategic & legal national framework



Updated HTA method guideline for medicines, 2023

For the first time in Ukraine, in pursuance of the Decree Cabinet of Ministers of Ukraine №1300, the guideline “State health technology assessment of medicines” was approved by the Order of the Ministry of Health dated 29.03.2021 № 593, with amendments approved by the Order of MOH № 1741 dated 06.10.2023



<https://moz.gov.ua/article/ministry-mandates/nakaz-moz-ukraini-vid-29032021--593-pro-zatverdzhennja-nastanovi-z-derzhavnoi-ocinki-medichnih-tehnologij-dlja-likarskih-zasobiv?fbclid=IwAR1whyAuMx-DGHN43ByK4h0XraWKwc3Qh2mmXA6gw0M706KT4Ro9Q3vax8o>

Capacity building and improvement of expertise of HTA team

In 2019-2024, experts of the HTA Department raised and continue to raise the level of their professional skills, knowledge and practical skills by participating in educational programs:

- capacity development program with the National Institute for Health Care and Excellence (NICE International) (2023-2024);
- completed project of the USAID "Safe and Affordable Medicines for Ukrainians" (SAFEMed) concerning the application of the horizon scanning tool and core principles of HTA with Radboud University, Netherlands (2023);
- with the Norwegian Institute of Public Health (NIPH) on medical technology demand forecasting for budget impact analysis (2024)
- with Krzysztof Landa, ex-adviser to the Minister of Health of Ukraine, ex-deputy Minister of Health of Poland, expert in the field of health care, evidence-based medicine, HTA for evaluating medical products (2023-2024);
- ISPOR short courses "Introduction to Modeling" and "Pharmacoeconomic Modeling – Applications" (2019);
- ongoing project of the USAID "Safe and Affordable Medicines for Ukrainians" (SAFEMed) regarding HTA for medical devices



Radboud Universiteit



Results of GAP analysis

Results of GAP analysis: methodological issues to set up a recommendation for cost effectiveness threshold ICER for all medicines/disease specific

Ukraine

Level of cost effectiveness	Indicator of cost effectiveness
Dominant	Less costly, higher benefit
Very cost effective	<1 GDP per capita
Cost effective	1-3 GDP per capita
Not very cost effective	3-5 GDP per capita
Not cost effective	Over 5 GDP per capita

*GDP per capita/ Ukraine (2021) = 131 944,00 UAH
(3 665 \$)*



UK, NICE (20 - 30 thousands GBP)

Level of cost effectiveness	Indicator of cost effectiveness
Very cost effective	< 0,6 GDP per capita
Cost effective	0,6-0,9 GDP per capita
Not cost effective	Over 0,9 GDP per capita


GDP per capita UK = 31 422,01 GBP (40 284,64 \$)

World Bank national accounts data, and OECD National Accounts data files
current US\$ - <https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=UA-GB>
current LCU - <https://data.worldbank.org/indicator/NY.GDP.PCAP.CN?locations=UA-GB>

Results of GAP analysis: methodological issues to set up a budget impact scale




Patient centricity results and impact: analysis of HTA recommendations in Ukraine



Managed entry agreements (MEA) introduction in Ukraine

- 38% recommendations to conduct MEA
- 12 MEA were implemented in 2022-2024





Perspectives for improvement of HTA methods in the nearest future

Perspectives for new HTA methods?

- Optimization approaches in HTA
- Setting up of ICER thresholds
- Setting up of BIA scale
- Alternative to naive treatment comparison assessment for single arm trials
- Benchmark to use AI tools (for example search strategies, data extraction)
- Approaches to analyze consistency between RCT and RWD, critical assessment of RWE
- New procedure for all member states of EU for implementation of Regulation (EU) 2021/2282 and conduct JCA for HTA
- Joint economic assessment and modelling, optional?

Oresta Piniashko, PhD

Director of HTA Department of SEC of Ministry of Health of Ukraine

Email: pinyazhko@dec.gov.ua, orestapb@gmail.com

tel.: +38 095 606 3533



Let's connect on LinkedIn

